Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy

Future Perspectives

Edited by
August 2022
224 pages
  • ISBN978-3-0365-5162-3 (Hardback)
  • ISBN978-3-0365-5161-6 (PDF)

This book is a reprint of the Special Issue Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy: Future Perspectives that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology

Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.

  • Hardback
© by the authors
acute kidney injury; early biomarker; plasma neutrophil gelatinase-associated lipocalin; soluble urokinase plasminogen activator receptor; medication optimization; older patients; emergency department; multimorbidity; polypharmacy; potentially inappropriate medication use; older adults; prevalence; determinants; chronic; outpatient; 2019 Beers criteria; Ethiopia; pharmacogenomics; polypharmacy; persons with diabetes; drug–drug interactions; drug–gene interactions; cytochrome P450; SLCO1B1; drug interaction checkers; adverse drug reactions; pharmacogenetics; pharmacogenomics; personalized medicine; phenprocoumon; DOACs; older adults; bleeding; thromboembolism; HLA; drug hypersensitivity; pharmacogenomics; abacavir; allopurinol; flucloxacillin; antiepileptic drugs; cost-effectiveness; shared medication record; medication reconciliation; drug information service; hospital pharmacy service; electronic prescribing; electronic medical record; clinical pharmacist; emergency department; CYP2D6; CYP2D7P; CYP2D8P; copy number variation; CNV; genotyping; 5’nuclease assay; HRM; high resolution melting; drug metabolization; pharmacogenetics; extracellular vesicles; pharmacogenomics; personalized medicine; exosomes; microvesicles; cytochrome P450; pharmacogene expression; medication review; deprescriptions; quality of life; aged; aged, 80 and over; nursing homes; deprescribing; medication-based risk score; deprescribing; polypharmacy; health outcomes; cytochromes; CYP1A2; adverse drug reaction; antipsychotics; olanzapine; clozapine; loxapine; pharmacogenetics; children; youth; polypharmacy; medication review; digital decision-support; health services research; general practice; process evaluation; pharmacogenetics; antidepressants; utility; population-based; older adults; appropriateness; medication adherence; digital health; adverse drug reactions; polypharmacy